Summary
Vindesine is a new vinca alkaloid with broadspectrum antineoplastic activity in experimental tumor models. Phase-I studies have shown that a weekly dosage regimen of 3–4 mg/m2 IV produces manageable toxicity, with leukopenia and peripheral neuropathy being dose-limiting. Two hundred seventy-five patients have been enlisted in Phase-II trials at the Memorial Sloan-Kettering Cancer Center. Major objective responses (complete and partial remissions) were seen in bronchogenic carcinomas, melanoma, testicular carcinoma, esophageal carcinoma, acute lymphocytic leukemia, malignant lymphoma (Hodgkin's and non-Hodgkin's) and Wilms' tumor. Patients with hematologic and germ cell neoplasms were treated on a daily administration schedule (1.0–1.3 mg/m2 IV for 5–7 days). Vindesine was well tolerated, with less than 5% of patients having a WBC nadir of<1000 cells/mm3 and with a platelet-sparing effect noted. Dose-related peripheral neuropathy occurred frequently and was generally mild to moderate in degree. Vindesine appears to be an active agent whose role will be further defined by completion of ongoing trials.
This is a preview of subscription content, log in via an institution to check access.
References
Bodey, G. P., Freireich, E. J.: Initial clinical studies of vindesine (desacetyl vinblastine amide sulfate). Proc. AACR/ASCO 17, 128 (1976)
Bodey, G. P., Lagakos, S. W., Gutierrez, A. C., Wilson, H. E., Selawry, O. S.: Therapy of advanced squamous carcinoma of the lung: cyclophosphamide versus “COMB”. Cancer 39, 1029–1031 (1977)
Currie, V., Wong, P., Tan, R., Tan, C., Krakoff, I.: Preliminary clinical studies of desacetyl vinblastine amide sulfate (DVA), a new vinca alkaloid. Proc. AACR/ASCO 17, 174 (1976)
Dyke, R. W., Nelson, R. L.: Phase I anti-cancer agents: vindesine (desacetyl vinblastine amide sulfate). Cancer Treat. Rev. 4, 135–142 (1977)
Krivit, W., Hammond, D.: Vindesine: A phase-II study by the Childrens Cancer Study Group. Curr. Chemother. 2, 1331–1334 (1978)
Livingston, R. B., Heilbrun L., Lehane, D., Costanzi, J. J., Bottomby, R., Palmer, R. L., Stucky, W. J., Hoogstraten, B.: Comparative trial of combination chemotherapy in extensive squamous carcinoma of the lung; a Southwest Oncology Group study. Cancer Treat. Rep. 61, 1623–1629 (1977)
Loeb, E., Hill, J. M., Pardue, A. S., Hill, N. O., Kahn, A., King, J. J., Hill, R.: Vindesine, a new vinca alkaloid, in the treatment of leukemia and lymphoma. Curr. Chemother. 2, 1332–1335 (1978)
Mathé, G., Misset, J. L., Vassal, F. de, Gouveia, J., Hayat, M., Machover, D., Belpomme, D., Pico, J. L., Schwarzenberg, L., Ribaud, P., Musset, M., Jasmin, C., Luca, L. de: Phase-II clinical trial with vindesine for remission induction in acute leukemia, blastic crisis of chromic myeloid leukemia, lymphosarcoma, and Hodgkin's disease: absence of cross resistance with vincristine. Cancer Treat. Rep. 62, 805–809 (1978)
Nelson, R., Dyke, R. W.: Phase I–II clinical investigation of vindesine (desacetyl vinblastine amide sulfate). Curr. Chemother. 2, 1328–1329 (1978)
Robertson, J. H., McCarthy, G. M.: Periwinkle alkaloids and the platelet count. Lancet 1969 2, 353–355
Tan, C.: Clinical and pharmacokinetic studies of vindesine in 50 children with malignant diseases. Curr. Chemother. 2, 1326–1328 (1978)
Wong, P. P., Yagoda, A., Currie, V., Young, C. W.: Phase II study of vindesine sulfate in the therapy for advanced renal carcinoma. Cancer Treat. Rep. 61, 1727–1729 (1977)
Young, C. W., Currie, V., Cvitkovic, E., Gralla, R., Wong, P.: Early Phase II evaluation of vindesine in patients with advanced cancer. Curr. Chemother. 2, 1330–1331 (1978)
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Gralla, R.J., Tan, C.T.C. & Young, C.W. Vindesine a review of phase-II trials. Cancer Chemother. Pharmacol. 2, 271–274 (1979). https://doi.org/10.1007/BF00257194
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00257194